Results 131 to 140 of about 6,419,415 (265)

Neutralization of the PTX3/CD44 axis suppresses TGF‐β1 signaling in kidney fibrosis

open access: yesFEBS Letters, EarlyView.
This study investigates how the PTX3/CD44 axis promotes kidney fibrosis by activating TGF‐β1 signaling. We demonstrate that the neutralizing antibody WHC‐001 effectively inhibits this pathway, suppressing myofibroblast activation and partial epithelial–mesenchymal transition (EMT).
Chao‐Chun Cheng   +8 more
wiley   +1 more source

Going viral − Virus‐targeting nanobodies for research, diagnostics and therapy

open access: yesFEBS Letters, EarlyView.
The increasing prevalence of viral diseases represents a major threat for global human health. Nanobodies, small binding fragments derived from camelid heavy‐chain antibodies, offer versatile tools for viral research, diagnostics, and antiviral therapy.
Domenic Ebert, Ulrich Rothbauer
wiley   +1 more source

Stop the Clot, Spread the Word: Cancer and Blood Clots

open access: yes
If you have cancer and are undergoing cancer treatment, you can protect your health by learning about your risk for life-threatening blood clots.Stop the Clot, Spread the Word\uae is a public education campaign made possible by funding provided to the ...

core  

Whole-blood viscosity and metabolic syndrome

open access: yes, 2012
Whole-blood viscosity (WBV) depends on vascular geometry and blood physiological constituents. Diabetes mellitus, hypertension, dyslipidemia and obesity – the major components of metabolic syndrome (MetS) – can independently affect blood vessels and ...
Nwose, Ezekiel Uba   +3 more
core   +1 more source

Unlocking the potential of cell‐permeable nanobodies for intracellular applications

open access: yesFEBS Letters, EarlyView.
This review outlines current strategies for delivery of nanobodies into cells and highlights recent examples of functional applications. By addressing and manipulating intracellular targets, these molecules hold great potential for treating cancer, respiratory diseases and neurological disorders, making this a vibrant area of research in the biomedical
Mariona Gené‐Verdés   +2 more
wiley   +1 more source

A retrospective study of B19 positive antigen blood donations [PDF]

open access: yes, 2001
Between August and December 2000 using ID-Parvovirus B19 – DiaMed, we studied 708 blood donations to detect b19 Ag on the plasma kept in our serum colletion, we found a prevalence of 0,424% positive donations.
Mercês, A   +5 more
core  

Tumour–host interactions in Drosophila: mechanisms in the tumour micro‐ and macroenvironment

open access: yesMolecular Oncology, EarlyView.
This review examines how tumour–host crosstalk takes place at multiple levels of biological organisation, from local cell competition and immune crosstalk to organism‐wide metabolic and physiological collapse. Here, we integrate findings from Drosophila melanogaster studies that reveal conserved mechanisms through which tumours hijack host systems to ...
José Teles‐Reis, Tor Erik Rusten
wiley   +1 more source

Blood Transfusion Service Board annual report 1999

open access: yes, 2000
I was appointed to chair the Board of the BTSB in April 1999 and have been engaged on a very deep learning curve since then. The organisation is in the throes of enormous changes under the very able direction of the CEO and the National Medical Director.
Blood Transfusion Service Board (BTSB)
core  

Circular RNA expression landscapes in myelodysplastic neoplasms: Associations with mutational signatures and disease progression

open access: yesMolecular Oncology, EarlyView.
In this explorative study, the abundance of circular RNA molecules in bone marrow stem cells was found to be elevated in patients with high‐risk myelodysplastic neoplasms, and to be associated with an increased risk of progression to acute myeloid leukemia.
Eileen Wedge   +17 more
wiley   +1 more source

IMPDH inhibition enhances cytarabine efficacy in SAMHD1‐expressing leukaemia cells via guanine nucleotide depletion

open access: yesMolecular Oncology, EarlyView.
Cytarabine is a key therapy for acute myeloid leukaemia (AML), but its efficacy is limited by the dNTPase SAMHD1, which hydrolyses its active metabolite. Screening nucleotide biosynthesis inhibitors revealed that IMPDH inhibitors selectively sensitise SAMHD1‐proficient AML cells to cytarabine.
Miriam Yagüe‐Capilla   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy